• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

作者信息

Muntinghe-Wagenaar M Benthe, Hiltermann T Jeroen N

机构信息

Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

出版信息

Transl Lung Cancer Res. 2025 Feb 28;14(2):328-333. doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.

DOI:10.21037/tlcr-24-966
PMID:40114950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11921232/
Abstract
摘要

相似文献

1
Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?晚期非小细胞肺癌中的新型免疫检查点抑制剂策略：迈向生物标志物驱动的疗法？
Transl Lung Cancer Res. 2025 Feb 28;14(2):328-333. doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.
2
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
3
In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.原位检测程序性细胞死亡蛋白1与程序性死亡配体1的相互作用作为非小细胞肺癌免疫检查点抑制反应的功能预测指标
J Thorac Oncol. 2025 May;20(5):625-640. doi: 10.1016/j.jtho.2024.12.026. Epub 2024 Dec 30.
4
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
5
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.2017年晚期非小细胞肺癌的新进展：免疫检查点抑制剂联合应用
J Thorac Dis. 2018 May;10(Suppl 13):S1534-S1546. doi: 10.21037/jtd.2018.04.99.
6
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.PD-L1 表达在非小细胞肺癌中的意义：作为预测和预后标志物的锐利双刃剑。
Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.
7
Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.PD-L1 抑制剂联合化疗与 PD-L1 抑制剂单药一线治疗晚期非小细胞肺癌的免疫相关不良反应：一项随机对照试验的荟萃分析。
Cancer. 2021 Mar 1;127(5):777-786. doi: 10.1002/cncr.33270. Epub 2020 Oct 29.
8
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.致癌驱动子亚型、程序性死亡受体-1 配体（PD-L1）评分和吸烟状态对驱动基因非小细胞肺癌患者 PD-1/PD-L1 抑制剂疗效的预测价值。
Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11.
9
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.肿瘤表达及作为生物标志物在伴有预先存在的间质性肺病的晚期非小细胞肺癌患者中程序性死亡配体 1 的作用。
Med Oncol. 2019 Apr 27;36(6):49. doi: 10.1007/s12032-019-1274-0.
10
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.

本文引用的文献

1
Baseline Blood CD8 T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.基线血液CD8 T细胞激活能力可区分非小细胞肺癌患者中对免疫检查点抑制联合立体定向放射治疗有反应者与无反应者。
Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592.
2
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.生物标志物导向的靶向治疗联合度伐利尤单抗治疗晚期非小细胞肺癌：一项 2 期伞式试验。
Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13.
3
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
CheckMate 9LA 随机试验中，一线纳武利尤单抗联合伊匹单抗加化疗治疗转移性非小细胞肺癌的 4 年临床更新和治疗转换调整结局。
J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189.
4
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.将基因组生物标志物相结合，以指导非小细胞肺癌的免疫治疗。
Clin Cancer Res. 2024 Apr 1;30(7):1307-1318. doi: 10.1158/1078-0432.CCR-23-4027.
5
The cancer-immunity cycle: Indication, genotype, and immunotype.癌症免疫周期：指征、基因型和免疫型。
Immunity. 2023 Oct 10;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011.
6
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.ATM 突变与 NSCLC 中独特的共突变模式和治疗弱点相关。
Clin Cancer Res. 2023 Dec 1;29(23):4958-4972. doi: 10.1158/1078-0432.CCR-23-1122.
7
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
8
Design and analysis of umbrella trials: Where do we stand?伞形试验的设计与分析：我们目前的进展如何？
Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022.
9
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.转移性非小细胞肺癌患者免疫治疗获得性耐药的临床定义。
Ann Oncol. 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. Epub 2021 Sep 3.
10
eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.电子鼻分析用于非小细胞肺癌的早期免疫治疗反应监测。
Lung Cancer. 2021 Oct;160:36-43. doi: 10.1016/j.lungcan.2021.07.017. Epub 2021 Aug 3.